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Abstract
The goal of this chapter is to acquaint the experienced injector with the technique of Non‐
surgical Rhinoplasty (NSR). This is an advanced technique and I am assuming that read‐
ers will be thoroughly familiar with how to perform cosmetic injections. I am also
assuming that readers are knowledgeable about the various fillers and injectables availa‐
ble today in the United States.
NSR provides the first noninvasive alternative to surgical rhinoplasty, accomplishing the
cosmetic goals of contour improvement without the risks and downtime of surgery. NSR
is not a replacement for rhinoplasty and is appropriate in a specific subgroup of rhino‐
plasty candidates, which will be characterized. The procedure is currently being per‐
formed in a variety of ways, as described in the literature review. This chapter will detail
the optimal methods of carrying out NSR based on a 10-year, 2500-patient experience
with the technique. Discussion will also include critical safety concerns, tips on how to
get the best results possible, and complication management. Being prepared for compli‐
cations is a particular concern with NSR because timely intervention is so critical in cases
of ischemic events. Patient selection, knowledge of the anatomy, meticulous technique,
and a focus on safety is the key to success with this procedure. Overall, NSR is safe, pre‐
cise, effective, and versatile. My patients are thrilled with their results, and I have made it
the foundation of a thriving practice.
Keywords: Rhinoplasty, injection, nonsurgical, Artefill, methyl methacrylate, Radiesse,
calcium hydroxylapatite, Voluma, hyaluronic acid, Restylane, Juvederm, nose job, ne‐
crosis, vascular embolism, ischemia, plastic surgery
1. Introduction
Surgical rhinoplasty remains one of the most popular cosmetic procedures performed on the
face. Statistics from the American Academy of Facial Plastic Surgery and the American Society
of Aesthetic Plastic Surgery put the number of rhinoplasties performed in the United States in
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2012 at around 190,000 [1,2]. This number is relatively unchanged from what it was in 1997,
prior to the FDA approval of cosmetic botulinum toxin and hyaluronic acid fillers. As with
any surgical procedure, patients undergoing rhinoplasty are subject to significant risks,
recovery time and expense. Until recently, patients who wanted to avoid surgery have never
had a viable alternative procedure that could accomplish the cosmetic goals of rhinoplasty
noninvasively. With the advent of long-lasting injectable fillers, however, physicians and
patients have embraced a nonsurgical surrogate.
I first performed primary Nonsurgical Rhinoplasty (NSR) using calcium hydroxyapatite
injectable filler in 2003, prior to the publication or report of such a procedure being done in the
United States. The novelty of the procedure caught the attention of the media, and I performed
it on several prominent national news programs and shows. This sparked the interest of the
public and doctors around the country began to offer NSR to their patients. Several small
studies have documented the safety and efficacy of the procedure since then [3,4,5]. Due to the
simplicity and efficacy of NSR, it has steadily grown in popularity over the last decade. Since
2003, I have had the privilege to perform over 2500 of these procedures in my clinic, using a
variety of injectable fillers, with great success.
2. History
The idea of injecting substances under the nasal skin to improve cosmesis is not new. Corning
and Gersuny first described injecting liquid paraffin into the nose to correct saddle nose
deformity at the beginning of the nineteenth century. The practice was quickly embraced but
just as quickly abandoned because of the severe long-term adverse effects of paraffin [6]. In
1919, Bruning tried to correct postoperative cosmetic nasal imperfections with fat injection [7].
The technique was ultimately not very well accepted because the fat grafts showed poor
survival duration [8]. In 1986, Webster presented a 20-year retrospective study of microdroplet
silicone injection into the nasal bridge to correct postsurgical nasal defects [9]. The study
reported mostly positive results, but many physicians, aware of horrific reports of complica‐
tions from the 1960s and 1970s, have remained wary of silicone injections.
The first modern study of NSR was published by Han et al. in 2006 [10]. It was an 11-patient
pilot study, looking at the safety and efficacy of dorsal augmentation NSR using hyaluronic
acid (Restylane, Medicis, Scottsdale, Ariz.) mixed with autologous fibroblasts. Hyaluronic acid
(HA) is a glycosaminoglycan that is a major component of connective, dermal, and neural
tissue in most mammals. Cross-linked HA has been widely used as an injectable filler since it
was FDA approved in 2003. Because of its biocompatibility, no allergy testing is required. The
HA in Restylane is produced by bacterial fermentation. The authors injected an average of 0.8
cc into the nasal dorsum of their patients, overcorrecting by 20%. Of the 6 patients that Han
et.al were able to get follow-up data on, there were no adverse events and the augmentation
effect was still persisting at 12 months. Later that year, Beer published a case report where he
successfully corrected a dorsal cosmetic defect with Restylane [11].
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Also that year, Laryngoscope published a report by Nyte where he successfully injected calcium
hydroxyapatite (CaHA, Radiesse, Merz, San Mateo, CA) to correct collapse of the internal nasal
valve in 23 patients [12]. Radiesse is a suspension of 30% of CaHA microspheres, 25–45µm in
size, in a mix of glycerin, carboxymethyl-cellulose, and water. It is fully biocompatible because
CaHA is identical to the mineral portion of human bone and teeth [13]. Radiesse was first
approved as a radiologic marker and for use in vocal fold augmentation. FDA approval for
cosmetic use came in 2006. Nyte’s technique of injecting through the inside of the nose seemed
to show some cosmetic correction along with the functional improvement. This is, however,
the only study that advocated intranasal injection.
Several papers emerged in the next year, including two small studies of Radiesse for cosmetic
improvement of the nose. In the paper by Stupak et al., the authors reported on a 13-patient
prospective single-arm trial with blinded evaluators of before and after pictures [5]. They
injected post-rhinoplasty patients seeking minor contour improvement. Areas injected
included dorsum, supratip, nasal sidewall, and ala. Mean amount injected was 0.18cc. They
did not inject the nasal tip due to concern that Radiesse would diffuse after injection and the
tip would lose definition. There were no adverse events and patient satisfaction and evaluator
ratings were good, but follow-up was only 2 months. Dayan et al. described their experience
with Radiesse NSR in 8 patients over the span of 2 years [14]. The volume they used ranged
from 0.3cc to 1.6cc and the corrections were mostly to the dorsum, radix, and supratip.
Duration of effect was estimated to be around 1 year. They encountered no complications. At
the end of their paper they made a point of mentioning that Dayan had performed revision
rhinoplasty on a patient who had received Radiesse 14 months earlier without complication.
The other paper that year was by De LaCerda et al. from Brazil [15]. They presented a 2-patient
experience with NSR using small amounts of porcine collagen on one patient (0.35 cc) and
hyaluronic acid (Voluma, Allergan, Irvine, Calif.) on the other (0.20 cc); follow-up was 4
months and 1 year, respectively. Areas injected included the nasofrontal angle, nasolabial
angle, the dorsum, and the tip.
In 2009, Humphrey and Dayan published a paper describing their preferences and techniques
of NSR in 22 patients with HA and an unspecified number with CaHA [16]. They advocated
using CaHA over HA because the latter absorbed water unpredictably. They considered
injecting significant amounts of HA into virgin noses dangerous due to the risk of vascular
compromise from the hydrophilic swelling of the product. They recommended injecting filler
subdermally and avoiding the tip and supratip area. The only complications that they observed
from the technique came after injecting HA into the tip area of two post-rhinoplasty patients,
one by Dayan and one by an outside injector. These were both cases of ischemia. Dayan’s
patient was a mild case of Raynaud’s-like phenomenon on the nasal tip and had no sequelae
due to treatment with Hyaluronidase. The outside injector’s case was a more serious case of
ischemia that resolved with Nitropaste and Hyaluronidase. Although necrosis was avoided,
they report that the patient developed aesthetically displeasing skin changes 1 year afterward.
Notably, they again write that Dayan has had no trouble performing rhinoplasty on post-
CaHA NSR patients. This is interesting because it contradicted numerous anecdotal accounts
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by other rhinoplasty surgeons at meetings and on the Internet that injectable fillers were
causing catastrophic scarring and damage to the nasal tissues [17].
In 2010, we published our 4-year experience with CaHA NSR, comprising 385 patients [18].
We injected virgin noses as well as patients who had undergone rhinoplasty surgery in the
past. We used volumes ranging from 0.3 cc to 0.5 cc of CaHA. We showed the procedure to be
extremely safe. Two serious complications were encountered in patients who had undergone
multiple revision rhinoplasties. They consisted of ischemia that progressed to small areas of
tissue necrosis at the tip and ala despite treatment with Nitropaste and oral steroids. The rate
of minor complications like cellulitis, prolonged swelling, or prolonged bruising was very low.
Interestingly, a history of previous rhinoplasty surgery did not increase the risk of minor
complications. The only exception was that post-rhinoplasty patients did have an increased
incidence of prolonged erythema. We documented successful injection of all areas of the nose,
including the tip, ala, dorsum, sidewall, and radix. We were surprised that the cosmetic effect
of CaHA did not, on average, last as long as we expected. A significant number of patients
showed evidence of resorption of the material as early as six months after injection.
In 2012, Kim and Ahn published a paper on a standardized NSR technique for Asian patients
using mostly CaHA (except for tip injection, where they used HA) [19]. They reported their
experience with 87 patients. Unlike most authors, they used 2% Xyocaine for anesthesia,
injecting the infratrochlear and external nasal nerves as well as placing boluses at the nasal tip
and the columnella-labial angle. Their technique consists of three steps. First, the columnella
and columnella-labial angle is augmented with an injection from the tip down to the nasal
spine. Second, the dorsum is augmented with a single injection, advancing the needle from
the tip to the radix and injecting upon withdrawal, as in the first step. The third step involves
shaping the tip with small, superficial bolus injections of HA. Four minor complications are
reported, none of them ischemic. They end the paper with a series of sensible guidelines to
avoid complications and achieve optimal cosmetic results.
In 2013, Kurkjian and Rohrich published their recommendations on technique for NSR [20].
The extent of their experience with the technique is not stated. They advocate low-pressure
injection with HA fillers only, using the smallest possible needles. According to them, Sculptra
and Radiesse should be avoided due to their irreversibility and the danger of long-term
palpability under relatively thin nasal skin. For patients desiring permanent nonsurgical
correction, permanent fillers should be avoided and fat should be used instead. They recom‐
mend using Restylane in all areas of the nose because it is relatively less hydrophilic. The
exception is the tip, where Juvederm is also recommended, taking advantage of postinjection
hydrophilic swelling for patients who want to increase tip fullness. In their experience, HA
has much higher longevity in the nose, lasting up to 2–3 years in some areas (I have not seen
evidence of this kind of duration in my HA NSR patients). They consider filler injection to be
useful in the correction of post-rhinoplasty contour irregularities.
This year I published a prospective, blinded study on the safety and efficacy of injecting methyl
methacrylate (Artefill, Suneva, Santa Barbara, CA) to correct nasal contour deficiencies [21].
Artefill is a third-generation methyl methacrylate filler in a collagen carrier that was FDA
approved in 2006 for nasolabial fold correction. The filler is 20% methyl methacrylate and 80%
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bovine collagen. Allergy testing for the carrier is commonly done 2 weeks prior to injection.
The particles are smooth and 30–50 microns in size. I have been using Artefill off-label for NSR
since 2006 with no complications in about 750 patients. In my experience, 3–5 injection sessions
are necessary because the body quickly absorbs the collagen carrier and the methyl metha‐
crylate stimulates fibroblast proliferation to a variable degree. For the study, I injected the
product over 3 sessions, spaced 1 month apart. Results were evaluated by me, an independent,
blinded MD evaluator, and the patient. With 1 year follow-up on 19 patients, we all observed
excellent cosmetic effect and no complications of any kind. An example of the results we
obtained is illustrated in Fig. 3.
3. Technique
NSR corrects mild or moderate cosmetic nasal irregularities. I perform this procedure to
achieve the following cosmetic goals:
1. Raise and better define an underdeveloped nasal dorsum. This is most popular among
my Asian patients.
2. Raise and better define a ptotic tip, as in Fig. 1.
3. Camouflage a dorsal bump. The dorsum is leveled by injecting filler above and below the
bump, as in Fig. 2.
4. Correct asymmetry of the tip or dorsum by subtly augmenting the weaker side.
5. Correct post-rhinoplasty contour defects. Most commonly, these present as saddle nose
deformity or other type of dorsal cartilage collapse, polly beak deformity, dorsal asym‐
metry due to asymmetric scarring, asymmetry of the tip due to postsurgical scarring or
cartilage over-resection and alar foreshortening.
Injectors around the world have used a variety of materials to achieve the aesthetic recon‐
touring of NSR. Currently, hyaluronic acid (HA) is the most popular filler material due to its
reversibility (via injection of Hyaluronidase). There are a number of reports and editorials on
technique in the literature. Most of these have been summarized above.
I consider HA, in its most common formulations of Juvederm and Restylane, to be the best
material for the beginner or the occasional injector of the nose. The ability to dissolve HA is a
critical safety feature for injectors who are not yet experts in the technique. Juvederm and
Restylane are effective for basic NSR goals, such as augmenting the bridge and camouflaging
minor dorsal bumps. These fillers struggle to perform, however, in the more advanced
applications of this technique. Juvederm and Restylane are relatively soft materials. They can
only provide moderate augmentation of the dorsum, they cannot lift a drooping tip very much
and they are poor at sculpting defining points of the tip and the sidewall of the nose. In my
experience, these HA fillers last an average of 6–8 months.
Perlane is a formulation of HA that is an improvement over Juvederm and Restylane for NSR.
Its increased density permits the advanced injector to sculpt more effectively. It has less of a
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tendency to spread, so better definition can be achieved. Perlane also lasts somewhat longer
in the nose than Juvederm and Perlane – about 8 months in my experience. Prior to the FDA
approval of Voluma, I used Perlane for patients who wanted the added safety of a reversible
filler.
I have used calcium hydroxyapatite (CaHA – Radiesse, MERZ Aesthetics Inc., San Mateo, CA)
in most of my NSR procedures. Radiesse received FDA approval in 2006 for correcting
Figure 1. CaHA NSR to lift a ptotic nasal tip and augment the nasal radix. The “Before” pictures are on top, “After” on
the bottom. The net result is a straighter nose on profile that appears smaller because it blends better into the rest of the
face.
Figure 2. HA NSR to camouflage a dorsal hump. The patient wanted to use a minimum of product to make her profile
straighter. She believed a slight curve would make her nose look more natural.
Miniinvasive Techniques in Rhinoplasty170
moderate to severe wrinkles and HIV-related facial volume changes. Prior to that it was
approved for vocal cord augmentation and I was using it off-label in the nose. As a non-HA
filler, CaHA is not reversible. Hypersensitivity reactions to CaHA are extremely uncommon
and reports of other adverse events do not differ significantly from reports for HA fillers. Side
effects noted of CaHA include:
• Nodules (generally associated with lip augmentation or injection in areas with little
subdermal space, e.g., infraorbital area) (Smith, 2007) (Tzikas, 2008)
• Granulomas (Lee MJ, 2008)
• Skin necrosis (Dayan SH and Arkins JP, 2011)
• Redness, erythema, and swelling (Siclovan, 2009)
The advantages of CaHA are its relative persistence of effect (average of 9–10 months in my
experience, but quite variable between 6 and 12 months) and its high density. This last quality
allowed me to effectively sculpt noses to my patients’ satisfaction. It is possible to significantly
elevate a droopy tip without excessive rounding. In fact, CaHA makes it possible to precisely
create aesthetically pleasing tip defining points in patients with rounded and poorly defined
tips. CaHA also makes it possible to significantly raise and add real definition to an underde‐
veloped dorsum – a quality that my Asian patients particularly appreciate.
With the FDA approval of Voluma in October of 2013, injectors gained a valuable new tool
that seems to confer longer duration of effect than any other filler. Voluma is more cross-linked
than other HA fillers and has a higher percentage of low molecular weight hyaluronic acid,
making it exceptionally smooth, viscous, and cohesive. Increased cross-linking makes the filler
more resistant to enzymatic degradation. Under study conditions, duration of effect was up
to 2 years [22], but anecdotal reports from the investigators indicate the filler to be even longer
lasting than that. Because of the duration of effect and its reversibility, I have been using
Voluma for the majority of my NSR cases over the last 5 months. It performs well for the most
part, but I find that in patients that need extensive elevation of their tip or dorsum, Radiesse
is still the only filler thick enough to provide the desired lift. In these patients, my NSR
combines Voluma and Radiesse.
I perform this procedure with the patient sitting up straight in the chair, as in Fig. 5. After
taking standardized photographs, I use a compounded triple anesthetic cream for 15–20 min
prior to the procedure (the materials I use are pictured in Fig. 4). My assistant will remove the
cream and the patient will ice the area to be injected. During the injection, my assistant taps
the patient’s contralateral shoulder to distract their attention from the injection. I have found
that alcohol works fine to clean the area and prevent infections. I prefer a thin-walled 29 gage
half-inch needle when using any of the fillers – Voluma, Radiesse, or Artefill. If that is not
available, I use a thin-walled 28 gage one-inch needle. I perform injections for the most part
as shallow linear threads, placing small amounts of filler as I withdraw the needle. I will place
filler into the area of the radix, dorsum, sidewall, tip, columnella, and ala as needed to correct
each individual irregularity. I will then massage and mold the filler to blend into the desired
contour. The patient goes home with instructions to avoid alcohol and strenuous exercise that
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day, as well as heavy sunglasses for two weeks. I agree with Kim and Ahn’s observation that
the volume effect of most fillers decreases by about 25% within the first month or two [19]. For
this reason, my procedure includes a complementary follow-up visit 3 weeks after the initial
injection, where I can touch-up the results.
In my experience, there are several types of patients that seek NSR. Most commonly, it is the
younger patient who cannot afford the time or resources required for postsurgical recovery.
They hear about the procedure through friends and the Internet. They mostly present with
mild or moderate cosmetic irregularities. Having studied the before and after pictures and
read about the procedure, they understand that it is not a technique that can physically reduce
the size of the nose, so I rarely see patients with severely large noses.
Figure 3. Artefill NSR to refine and straighten the dorsum and tip from both the profile and straight on views. This
patient wanted to have a thinner appearing nose from the frontal view and a straighter and more refined looking dor‐
sum and tip from the profile.
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About a third of my NSR patients are Asian, as in Fig. 6. These patients commonly desire an
increase in the height and definition of their dorsum and radix, as well as improvement in the
definition and projection of their nasal tip. These patients are usually young and cannot afford
surgery. They are also often wary of unnatural surgical results, describing people with visible
or overly large dorsal grafts that they have seen in the Asian community. Like many patients
who opt for this procedure, they want to see the cosmetic change they desire, but only if their
nose retains a natural appearance and no one can tell that they have had an aesthetic procedure.
Both of these kinds of patients usually choose the temporary procedure using a CaHA filler
like Radiesse or an HA filler like Perlane or Voluma. They are aware that I commonly use
Artefill for long-lasting to permanent results but want to try out the effect before they commit.
Once the effect fades, some of these patients decide to continue with the temporary filler but
many switch over to Artefill.
Another common category of patients presenting for this procedure are the ones who have
desired cosmetic improvement in their nose for a long time, but have been afraid of surgical
Figure 4. Equipment necessary for NSR. Radiesse, Voluma, and Perlane are all displayed with the first two as presplit
half syringes (using a Luer-Lock connector and a 1cc syringe). I try to use the smallest possible needle gage – 27 or 28 G
thin-walled needles are my preference. The photograph displays the four main methods of pain control in my injecta‐
bles practice. Topical numbing cream is a compounded 23% Lidocaine, 7% Tetracaine mixture. Ice and a stress ball are
important, but most important is my assistant’s hand, which distracts the patient by tapping on the shoulder opposite
to where I am standing.
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and anesthesia risks. These patients present with a variety of aesthetic complaints. Most are
appropriate for the NSR technique, but some require reduction and have to be turned away.
An important subset of the above patient group is those who consider their aesthetic complaint
to be too minor to undergo surgical correction. They are bothered by their small bump or mild
asymmetry but feel that surgery exacts too high of a price (both financial and temporal). These
patients are mostly ideal candidates for NSR. A small amount of contour correction to restore
symmetry or camouflage a small bump makes them very happy.
About a quarter of my patients have already had one or more surgical rhinoplasties. These
patients present with a variety of aesthetic complaints, but all of them are disappointed in the
aesthetic result of their surgery (or surgeries) and desire an effective alternative. Some opt for
temporary fillers, but many choose methyl methacrylate so that they can “get it over with.”
Figure 7 illustrates one of those patients. Anyone who performs NSR must be aware that these
patients present with technically challenging problems. Postsurgical scarring stiffens the skin
Figure 5. Correct patient position for NSR. She is relaxed and sitting comfortably with her head resting on the back of
the chair. Movement is minimized. There is no tissue redistribution, as there would be if the patient was lying flat, so
cosmetic results are optimally accurate.
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and limits the lift that can be achieved with filler injection. Injectors need to take care not to
over-promise these patients. Their results are going to be, for the most part, relatively subtle.
Most importantly, postsurgical skin has a more tenuous blood supply, especially around the
tip and ala. The risk of ischemia and necrosis are significantly increased in these patients. Only
the most experienced injectors should be treating them, since the complications of necrosis can
be catastrophic.
Complications of NSR are relatively rare. This is not surprising, since the overall major
complication rate for filler injections has been estimated to be less than one hundredth of one
percent [4]. As described above, published studies are meager and mostly small, but they
report few serious adverse events. Bruising, transient erythema, and short-term swelling
represents most of the issues documented. The exceptions are the disturbing case reports that
detail blindness and major necrosis of nasal tissue [5,6,7]. Since the doctors treating the
complications and not those who injected the patients write most of these reports, conclusions
about needle type, injection technique, and even material used are often difficult. Of the reports
published by the actual injectors, we know that sudden pain, blanching, duskiness, and
ecchymosis in the area being injected are all danger signals for ischemia and necrosis. Com‐
promise of the blood supply to the skin in cases of filler injection can be caused by either
intravascular embolism or small vessel compression by the filler.
Opthalmalgia and visual loss within minutes are signs of retinal artery embolism. Other signs
of ophthalmic vasculature embolism include immediate diaphoresis, nausea, headache,
opthalmoplegia, and ptosis [4].
In my experience, these complications can best be avoided by understanding the anatomy,
always practicing safe injection technique, and having well-prepared protocols ready to launch
Figure 6. CaHA NSR to augment and better define a nasal bridge and tip in an Asian patient.
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at any sign of danger. Our traditional understanding of the vascular anatomy of the external
nose is illustrated in Fig 8.
A good injector is especially careful when injecting the radix and nasal sidewall, to avoid the
dorsal nasal and angular branches, respectively. Based on Fig. 8, keeping one’s injection points
in the midline seems to ensure safety. This is surely true to some degree, but a recent paper
by Saban et al. proposes that the external nasal vasculature is more interconnected than we
think [23].  Using cadaver dissection and ultrasonography study of  live subjects,  the au‐
thors conclude that  anastomoses between the internal  and external  carotid vascular sys‐
tems are plentiful in the external nose. This plexus of vessels is located in the SMAS layer.
Safe injection technique should therefore focus on keeping the needle deep instead of trying
to avoid specific vessels.
Figure 7. Artefill NSR to correct postsurgical contour irregularities and asymmetry of the dorsum and to lift the nasal
tip. Lower series are 1 year after the last of three sessions of Artefill injections.
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Some clinicians have recommended aspiration prior to injection of filler in order to avoid
vascular embolism. In my experience, this is a cumbersome practice with questionable benefits.
Most fillers are thick gels. Building up enough negative pressure for aspiration of blood takes
a lot of hand force and would only work for Voluma due to its smooth viscoelastic properties.
Even in experienced hands, by the time one aspirates and then injects, the needle is no longer
in the same place, rendering the test useless.
Rather than aspirating, I think that following accepted best practice standards for injecting
filler is a more reliable way of preventing complications [8,9]:
1. Needles should be as small as possible so that filler flow rate is low.
2. Fillers should always be injected slowly and under low pressure, especially in the nasal
area. The blindness complications in the literature occurred because a filler embolus was
injected with enough force to overcome systolic blood pressure and travel up into the
ophthalmic vasculature. Gentle injection technique should prevent this complication.
3. The needle should be advanced through the skin slowly and filler should only be flowing
when the needle is moving out of the skin. This way, even if the tip of the needle is inside
the lumen of a vessel at some point, only a tiny amount of filler will enter the vessel, as
the needle will be out in the next moment.
4. Small volumes of filler should be introduced with each injection.
5. We always ice prior to injection. Ice decreases pain and shrinks blood vessels, making
them less likely to be punctured.
Figure 8. External arterial anatomy of the nose. Vessels originating from the External Carotid are in red, whereas those
in black come from the Internal Carotid via the Opthalmic Artery.
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Some authors advocate blunt tipped cannulas for all filler injection as a way to reduce
complications and discomfort [10,11]. I think this is not a good idea in the nose. The weakness
of cannulas is precision. It is much easier to know the exact location of a needle tip than the
tip of a cannula that bends easily as it is advanced through the tissue. The aesthetics of the
nose are particularly sensitive to the smallest contour asymmetries. One millimeter of fullness
difference between two sides of the tip is clearly noticeable. One-millimeter deviation from the
midline, when augmenting a dorsum, makes the nose appear off-center.
The literature contains reports of severe complications from every type of filler available, and
I have successfully used a variety of materials in the nose. I do not believe that there is a material
contraindicated for nasal injection. It is the skill and knowledge of the injector that is para‐
mount to the success of the procedure.
While not really a complication, vaso-vagal episodes can be disturbing to the novice injector.
Diaphoresis, sudden pallor, a sensation of nausea are all warning signs of an impending
episode. It is more likely to happen if the patient has not eaten much prior to their appointment.
In the setting of cosmetic injections, patients become vaso-vagal primarily because they are
holding their breath in anticipation of pain. The frequency of these episodes dropped dramat‐
ically once we began to routinely remind our patients to breathe. Distraction shoulder tapping
also helps them tolerate the injections without excessive anxiety. If the patient does become
vaso-vagal, our routine is to immediately place them in reverse Trendelenberg position,
increasing blood flow to the brain. We place an ice bag behind their neck and give them
something sweet to drink like orange juice or Coke. We monitor their pulse and blood pressure
manually. Most patients will recover fully within a few minutes. We have not yet had to use
smelling salts.
Complication management starts with the preventative measures outlined above. If, however,
the clinician suspects that an ischemic event is unfolding, there are immediate steps that he or
she should be ready to take. First, injection should stop immediately. The area should be
massaged vigorously in an effort to restore blood flow and Hyaluronidase should be injected
into the area. A dose of 50–80 units should be sufficient. Even if a non-hyaluronic acid filler
has been used, Hyaluronidase is useful because it dissolves some native hyaluronic acid and
decreases interstitial pressure, easing blood flow. Topical 2% Nitroglycerin paste (Nitro-bid.
Savage Labs, Melville NY) should be in the room and readily available to anyone performing
this procedure. It is a great vasodilator that acts very quickly. In situations of potential
ischemia, a small amount should be applied to the area in question and it should stay on for
at least 15 min. The patient should take aspirin 325 mg immediately. If the skin becomes pink
again and remains so after a period of observation of 15 min or so, I would feel comfortable
sending the patient home on aspirin every 4 h for a day, warm compresses, and periodic
massage of the area. If the skin becomes dusky, I would reapply the Nitropaste for another 30
min and consider reinjecting the area with Hyaluronidase. I would observe the patient in the
office for the next hour or so, applying warm compresses and massaging the area. At this point,
the patient should begin oral steroid therapy and oral antibiotics. I would give them a Medrol
dose pack and make sure that they take the first dose right away. At this point, the patient
should be seen in the office on a daily basis to monitor the progression of tissue damage. If
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damage continues to unfold, the injector should consider hyperbaric oxygen therapy and
referral to a plastic surgeon. My in-room safety kit, a.k.a. injectables “crash cart” is illustrated
in Fig. 9.
Figure 9. My in-room safety kit. Pictured are Hyaluronidase, Nitopaste, Aspirin, Kenalog, Solu-medrol, and smelling
salts. These are the medications important to have on hand in every room.
When performed safely and correctly by an experienced and well-trained injector, NSR is a
procedure that yields excellent patient satisfaction. It is not a replacement to rhinoplasty for
all patients and I continue to refer those that are not candidates (mostly patients who need
significant reduction) to my surgical colleagues. This procedure does, however, provide a
valuable alternative to traditional surgery. It increases the pool of people wanting cosmetic
correction of the nose, bringing in a significant population of patients who would never do
surgery. In fact, recalling the statistics from AAFPRS and ASAPS, over the last 10 years that
this procedure has become popular, it has not cut into the number of patients receiving surgical
rhinoplasty [1,2]. For the patients who are candidates, it saves them expense, risk, and
downtime. Finally, the precision of filler injection means that this procedure is in some cases
superior to surgery in accomplishing patients’ cosmetic goals. I have built a large practice upon
this procedure and continue to receive many referrals from happy patients.
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